Taiwan-based contract drugmaker Bora Pharmaceuticals has entered into a major partnership with drug discovery company Insilico Medicine, with the collaboration potentially worth more than $2.5 billion if fully carried out, Insilico announced Wednesday.
According to Insilico, the two companies plan to explore ways to introduce automation across several areas, including pharmaceutical development, process optimization, and quality systems. The partnership is also expected to put Insilico’s technology to work improving efficiency in manufacturing, supply chain management, distribution, and corporate operations.
Bora CEO Bobby Sheng described the vision behind the deal in a statement: “Together, we aim to build a scalable and repeatable model that can advance promising drug candidates more efficiently, positioning Bora at the forefront of AI-enabled pharmaceutical development and manufacturing, and establish a long-term growth platform through the development and commercialisation of high-value proprietary assets.”
Insilico Medicine has been active in forming partnerships across Asia. The company has previously announced agreements with China Medical System and Japan’s Takeda Pharmaceutical, among other drugmakers in the region.
